Biotech Values

[DewDiligence]

Dr. Topol wonders if something untoward is occurring in the FDA review of Eliquis:

http://blogs.theheart.org/topolog/2012/6/26/there-is-something-strange-about-apixiban

This 5-minute video presents as more of a Topol editorial about the opacity of FDA CRL’s than a bona fide question about Eliquis per se.

My opinion, FWIW, is that BMY/PFE’s statement in #msg-76926354 should be taken at face value—i.e. that the Eliquis CRL can be easily and quickly rectified.